PE20120766A1 - Derivados de quinoxalina como inhibidores de tumores - Google Patents
Derivados de quinoxalina como inhibidores de tumoresInfo
- Publication number
- PE20120766A1 PE20120766A1 PE2011001740A PE2011001740A PE20120766A1 PE 20120766 A1 PE20120766 A1 PE 20120766A1 PE 2011001740 A PE2011001740 A PE 2011001740A PE 2011001740 A PE2011001740 A PE 2011001740A PE 20120766 A1 PE20120766 A1 PE 20120766A1
- Authority
- PE
- Peru
- Prior art keywords
- substituted
- alkyl
- quinoxalin
- urea
- halogen
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical class N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004202 carbamide Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 abstract 1
- -1 AMINO Chemical class 0.000 abstract 1
- 108010006654 Bleomycin Proteins 0.000 abstract 1
- 190000008236 CARBOPLATIN Chemical compound 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 abstract 1
- 229960001561 bleomycin Drugs 0.000 abstract 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 229960001904 epirubicin Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I, DONDE X ES O,S; R1 ES H, ALQUILO C1-C12 SUSTITUIDO O NO, CIANO, HALOGENO; R2 Y R3 SON CADA UNO H, ALQUILO C1-12 SUSTITUIDO O NO; R4 ES H, CICLOALQUILO SUSTITUIDO O NO, HETEROCICLILO SUSTITUIDO O NO; ALQUILARILO SUSTITUIDO O NO, ENTRE OTROS; R5, R6, R7 Y R8 SON CADA UNO H, ALQUILO C1-C12 SUSTITUIDO O NO, ARILO SUSTITUIDO O NO, HETEROARILO SUSTITUIDO O NO, HALOGENO, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-CICLOPENTIL-3-[7-(4-HIDROXI-3-METOXIFENIL)QUINOXALIN-2-IL]UREA; 1-[7-(3,4-DIMETOXIFENIL)QUINOXALIN-2-IL]-3-[1-(2,2,2-TRIFLUOROACETIL)PIPERIDIN-4-IL]UREA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS BLEOMICINA, CARBOPLATINO, EPIRUBICINA, IRINOTECAN, VINCRISTINA, ENTRE OTROS, SIENDO UTIL EN EL TRATAMIENTO DE CARCINOMAS METASTASICOS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16595309P | 2009-04-02 | 2009-04-02 | |
| EP09157141A EP2241557A1 (de) | 2009-04-02 | 2009-04-02 | Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120766A1 true PE20120766A1 (es) | 2012-07-19 |
Family
ID=40886691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001740A PE20120766A1 (es) | 2009-04-02 | 2010-03-25 | Derivados de quinoxalina como inhibidores de tumores |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8394801B2 (es) |
| EP (2) | EP2241557A1 (es) |
| JP (1) | JP5583201B2 (es) |
| KR (1) | KR20110136888A (es) |
| CN (1) | CN102378758A (es) |
| AR (1) | AR075935A1 (es) |
| AU (1) | AU2010233983A1 (es) |
| BR (1) | BRPI1010306A2 (es) |
| CA (1) | CA2757138A1 (es) |
| CO (1) | CO6501171A2 (es) |
| EC (1) | ECSP11011363A (es) |
| IL (1) | IL215025A0 (es) |
| MX (1) | MX2011010329A (es) |
| NZ (1) | NZ595064A (es) |
| PE (1) | PE20120766A1 (es) |
| RU (1) | RU2532914C2 (es) |
| SG (1) | SG175014A1 (es) |
| TW (1) | TWI464150B (es) |
| UA (1) | UA105211C2 (es) |
| WO (1) | WO2010115719A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464675A (zh) * | 2010-11-12 | 2012-05-23 | 上海医药工业研究院 | 具有抗肿瘤活性的金络合物及其可药用衍生物 |
| CA2842976A1 (en) | 2011-07-26 | 2013-01-31 | Grunenthal Gmbh | Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
| JP2018525371A (ja) * | 2015-07-30 | 2018-09-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アリール置換された二環式ヘテロアリール化合物 |
| WO2017205536A2 (en) * | 2016-05-24 | 2017-11-30 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| CN110698418B (zh) * | 2019-09-11 | 2022-07-01 | 广西师范大学 | 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用 |
| CN115463217B (zh) * | 2021-06-11 | 2024-03-12 | 深圳埃格林医药有限公司 | 己酸羟孕酮在增强肿瘤治疗效果中的应用 |
| CN114605391B (zh) * | 2022-02-21 | 2024-01-26 | 广州六顺生物科技股份有限公司 | 喹喔啉类衍生物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN842196A0 (en) | 1996-03-05 | 1996-03-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| EA004103B1 (ru) | 1997-05-28 | 2003-12-25 | Авентис Фармасьютикалз Продактс Инк. | ХИНОЛИНОВЫЕ И ХИНОКСАЛИНОВЫЕ СОЕДИНЕНИЯ, ИНГИБИРУЮЩИЕ ТИРОЗИНКИНАЗЫ ТРОМБОЦИТАРНОГО ФАКТОРА РОСТА И/ИЛИ p56 |
| IL139783A0 (en) | 1998-06-01 | 2002-02-10 | Shionogi & Co | Cyanoiminoquinoxaline derivates |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| AU2003243318A1 (en) * | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| WO2008015423A1 (en) | 2006-08-01 | 2008-02-07 | Sentinel Oncology Limited | Quinoline and quinoxaline n-oxides as chk-1 inhibitors |
| EP1990342A1 (en) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
| CL2008001356A1 (es) | 2007-05-10 | 2008-11-14 | Smithkline Beecham Corp | Compuestos derivados de quinoxalina, inhibidores de la pi3 quinasa _(p13ka, pi3ko, pi3b y/o pi3ky); composicion farmaceutica; uso para tratar un trastorno autoinmune, enfermedad inflamatoria, cardiovascular, neurodegerativa, alergia, asma, enfermedad renal, cancer, rechazo de transplante, lesiones pulmonares. |
-
2009
- 2009-04-02 EP EP09157141A patent/EP2241557A1/de not_active Withdrawn
-
2010
- 2010-03-25 EP EP10710051A patent/EP2419411A1/en not_active Withdrawn
- 2010-03-25 US US12/731,243 patent/US8394801B2/en not_active Expired - Fee Related
- 2010-03-25 SG SG2011071610A patent/SG175014A1/en unknown
- 2010-03-25 AR ARP100100940A patent/AR075935A1/es unknown
- 2010-03-25 RU RU2011138477/04A patent/RU2532914C2/ru not_active IP Right Cessation
- 2010-03-25 NZ NZ595064A patent/NZ595064A/xx unknown
- 2010-03-25 KR KR1020117026033A patent/KR20110136888A/ko not_active Withdrawn
- 2010-03-25 MX MX2011010329A patent/MX2011010329A/es active IP Right Grant
- 2010-03-25 JP JP2012502582A patent/JP5583201B2/ja not_active Expired - Fee Related
- 2010-03-25 TW TW099108919A patent/TWI464150B/zh not_active IP Right Cessation
- 2010-03-25 CA CA2757138A patent/CA2757138A1/en not_active Abandoned
- 2010-03-25 WO PCT/EP2010/053891 patent/WO2010115719A1/en not_active Ceased
- 2010-03-25 UA UAA201111539A patent/UA105211C2/ru unknown
- 2010-03-25 BR BRPI1010306A patent/BRPI1010306A2/pt not_active IP Right Cessation
- 2010-03-25 PE PE2011001740A patent/PE20120766A1/es not_active Application Discontinuation
- 2010-03-25 CN CN201080014936XA patent/CN102378758A/zh active Pending
- 2010-03-25 AU AU2010233983A patent/AU2010233983A1/en not_active Abandoned
-
2011
- 2011-09-07 IL IL215025A patent/IL215025A0/en unknown
- 2011-09-30 CO CO11128635A patent/CO6501171A2/es active IP Right Grant
- 2011-09-30 EC EC2011011363A patent/ECSP11011363A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP11011363A (es) | 2011-10-31 |
| RU2011138477A (ru) | 2013-05-10 |
| KR20110136888A (ko) | 2011-12-21 |
| BRPI1010306A2 (pt) | 2017-05-16 |
| US8394801B2 (en) | 2013-03-12 |
| CO6501171A2 (es) | 2012-08-15 |
| JP2012522741A (ja) | 2012-09-27 |
| IL215025A0 (en) | 2011-11-30 |
| CA2757138A1 (en) | 2010-10-14 |
| AU2010233983A1 (en) | 2011-10-06 |
| RU2532914C2 (ru) | 2014-11-20 |
| NZ595064A (en) | 2013-10-25 |
| AR075935A1 (es) | 2011-05-04 |
| CN102378758A (zh) | 2012-03-14 |
| EP2241557A1 (de) | 2010-10-20 |
| SG175014A1 (en) | 2011-11-28 |
| TW201100391A (en) | 2011-01-01 |
| JP5583201B2 (ja) | 2014-09-03 |
| WO2010115719A1 (en) | 2010-10-14 |
| UA105211C2 (ru) | 2014-04-25 |
| US20100266538A1 (en) | 2010-10-21 |
| TWI464150B (zh) | 2014-12-11 |
| MX2011010329A (es) | 2011-10-17 |
| EP2419411A1 (en) | 2012-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120766A1 (es) | Derivados de quinoxalina como inhibidores de tumores | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| PE20130647A1 (es) | Indoles | |
| PE20050087A1 (es) | Derivados de 2-oxodihidropiridina n-sustituidos | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20121282A1 (es) | Antagonistas de espiro-oxindol de mdm2 | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| PE20090718A1 (es) | Derivados de espiroindolinona | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| PE20130229A1 (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer | |
| PE20091095A1 (es) | Moduladores de gamma secretasa | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PE20142185A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| PE20071322A1 (es) | Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20080345A1 (es) | Derivados de piperazina como agonistas del receptor de gpr38 | |
| PE20190175A1 (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| PE20170664A1 (es) | Agonistas del receptor de apelina(apj) y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |